Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fampridine for Working Memory in Healthy Subjects
NCT04652557Phase 2Completed
- Start
- Nov 2021
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dalfampridine in schizophrenia, major depressive disorder (MDD). Started Nov 2021; status: completed.
02
Drugs
dalfampridine
03
Conditions
schizophreniamajor depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04652557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04652557.